Clinical trial · no report yet · Phase 2/Phase 3
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06712316 ↗
- Recruiting
- BioNTech SE
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pumitamig; Pembrolizumab; Carboplatin; Pemetrexed; Paclitaxel
- Arms
- Substudy A Phase 2 (Arm 1) - Pumitamig Dose 1 + Carboplatin + Pemetrexed · Experimental
- Substudy A Phase 2 (Arm 2) - Pumitamig Dose 2 + Carboplatin + Pemetrexed · Experimental
- Substudy A Phase 2 (Arm 1A - China only) - Pumitamig Dose 3 + Carboplatin + Pemetrexed · Experimental
- Substudy A Phase 3 (Arm 3) - Pumitamig Dose 3 + Carboplatin + Pemetrexed · Experimental
- Substudy A Phase 3 (Arm 4) - Pembrolizumab + Carboplatin + Pemetrexed · Active comparator
- Substudy B Phase 2 (Arm 1) - Pumitamig Dose 1 + Carboplatin + Paclitaxel · Experimental
- Substudy B Phase 2 (Arm 2) - Pumitamig Dose 2 + Carboplatin + Paclitaxel · Experimental
- Substudy B Phase 2 (Arm 1A, China only) - Pumitamig Dose 3 + Carboplatin + Paclitaxel · Experimental
- Substudy B Phase 3 (Arm 3) - Pumitamig Dose 3 + Carboplatin + Paclitaxel · Experimental
- Substudy B Phase 3 (Arm 4) - Pembrolizumab + Carboplatin + Paclitaxel · Active comparator
- Enrollment
- 1,580 (estimated)
- Primary outcomes
- Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs
- Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)
- Phase 2 - Objective response rate (ORR)
- Phase 2 - Best percentage change from baseline in tumor size
- Phase 3 - Progression free survival (PFS) assessed by BICR
- Sponsor
- BioNTech SE with Bristol-Myers Squibb
- Start
- Jan 7, 2025
- Primary completion
- Jan 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06712316 · updated Sep 22, 2026